First human trial tests custom RNA vaccines tailored to each Patient's cancer
NCT ID NCT02316457
Summary
This Phase 1 trial tested two personalized RNA vaccines designed to train the immune system to attack triple-negative breast cancer cells. The study involved 42 patients who had completed standard treatments like surgery and chemotherapy. Researchers created custom vaccines for each patient based on their specific tumor characteristics to see if this approach was safe and could trigger an immune response against cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER (TRIPLE NEGATIVE BREAST CANCER (TNBC)) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dr. Horst Schmidt-Kliniken Wiesbaden
Wiesbaden, 65199, Germany
-
Johannes Gutenberg University
Mainz, RLP, 55131, Germany
-
National Center for Tumor Diseases (NCT)
Heidelberg, 69120, Germany
-
Uppsala University Hospital
Uppsala, 75185, Sweden
Conditions
Explore the condition pages connected to this study.